三葉草生物-B(02197.HK)與江蘇亞盛醫藥開發訂立聯合療法合作協議
格隆匯12月9日丨三葉草生物-B(02197.HK)公吿,於2021年12月9日,公司全資附屬公司Clover Biopharmaceuticals (HongKong) Co.,Limited,與江蘇亞盛醫藥開發有限公司訂立了聯合療法合作協議。
江蘇亞盛為一家生物醫藥公司,主要從事小分子藥品的研發及商業化,為亞盛醫藥集團的全資附屬公司。亞盛醫藥的股份於香港聯合交易所有限公司主板上市(股份代號:6855)。
根據合作協議,訂約方將共同評估公司旗下重組人TRAIL-三聚體融合蛋白(SCB-313)和亞盛醫藥在研SMAC模擬物╱凋亡蛋白抑制因子(IAP)靶向療法小分子拮抗劑(APG-1387)在1b/2期臨牀試驗中聯用治療晚期腹膜癌的效果。
亞盛醫藥將與集團共同開展這項開放性、多中心的1b/2期臨牀研究,用於評估APG-1387和SCB-313聯合療法在治療原發性或繼發性(不同原發腫瘤來源)腹膜癌患者的安全性、耐受性、藥代動力學╱藥效動力學特徵和療效。該試驗將在中國和澳大利亞的多個地點開展。
訂立合作協議有益於訂約方探索針對腹膜癌患者的創新型治療方案及手術替代方案,並可望藉由靶向作用於細胞凋亡通路中的不同環節,這一聯合療法的協同效益將對患者大有裨益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.